Cryo-Cell International

Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage, and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded in 1989 and is headquartered in Oldsmar, FL.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MIAMI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International announces that Chairman of the Board and Co-CEO, David Portnoy, will be presenting at the Q3 Virtual Investor Summit on August 18 th , 2021.

Cryo-Cell International to Present at the Q3 Virtual Investor Summit

OLDSMAR, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2021.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2021 Financial Results

CCEL is undervalued, given the overlooked Duke contract.

Cryo-Cell International: Overlooked Duke Contract Signals Business Inflection

MIAMI, May 10, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell's Medical Director, Dr. Joanne Kurtzberg and her research team at The Marcus Center for Cellular Cures (MC3) at Duke University School of Medicine are currently conducting two major studies: MASC (Phase 1/2) & MISTIC (Phase 1) to treat, respectively, COVID-19 related Acute Respiratory Distress Syndrome ‎(ARDS) and COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS -‎C)‎. ‎

Cryo-Cell International Proudly Announces Two Ongoing COVID-19 Related Trials

OLDSMAR, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2021.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2021 Financial Results

News for Cryo-Cell International Stock (CCEL)